CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: imagingstrokeacutectischemic
  Phrases that lowered it: blood pressuremmhgand safetyefficacy anddiseases
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 23 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: single (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 73.0% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 47363 (raises risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 80 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III NCT05141305 · started 2022 · scored riskier than 43% of active trials completed
• Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion NCT06221371 · started 2024 · scored riskier than 56% of active trials completed
• CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase NCT04086147 · started 2019 · scored riskier than 31% of active trials completed
• Tenecteplase in Stroke Patients Between 4.5 and 24 Hours NCT03785678 · started 2019 · scored riskier than 94% of active trials completed
• Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke NCT01949948 · started 2012 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.